Chronic lymphocytic leukemia diagnosis involves several tests that help healthcare professionals identify abnormal lymphocytes and understand the characteristics of the disease. Blood tests are often an important starting point, while flow cytometry can help determine the type of cells involved. Additional examinations, including genetic and molecular testing, imaging, or bone marrow assessment, may be used in specific situations. These testing methods can provide information about disease features and support decisions about monitoring and management. Understanding how CLL is diagnosed can help patients and families become more familiar with the medical evaluation process and the purpose of different tests.
Chronic lymphocytic leukemia, commonly called CLL, is a type of cancer that affects lymphocytes, which are white blood cells involved in the immune system. Diagnosis generally begins when changes in blood cell counts are identified during routine testing or when a person undergoes medical evaluation for certain symptoms. Healthcare professionals use a combination of laboratory tests and clinical assessments to confirm CLL and gather information about its characteristics.
A complete blood count, or CBC, is often one of the first tests used when evaluating possible CLL. This test measures different components of the blood, including red blood cells, white blood cells, and platelets. An increased number of lymphocytes may lead to further investigation, although a high lymphocyte count alone does not confirm CLL.
Flow cytometry is an important laboratory method used to examine specific markers on the surface of blood cells. This testing can help identify whether a group of lymphocytes has characteristics associated with CLL and distinguish them from other blood and lymphatic conditions.
Key parts of the initial diagnostic process may include:
These assessments help healthcare professionals build a clearer picture of blood cell changes. In many cases, blood-based testing provides significant information for diagnosing CLL without immediately requiring more invasive procedures.
After CLL is identified, additional tests may be performed to understand certain biological features of the leukemia cells. Genetic and molecular testing can identify chromosome changes or other characteristics that may provide information about how the condition behaves. These tests are generally used alongside other clinical findings rather than as standalone diagnostic tools.
Fluorescence in situ hybridization, often called FISH testing, is one method that can detect specific chromosome abnormalities in CLL cells. Other laboratory assessments may examine gene mutations or the immunoglobulin heavy chain variable region, also known as IGHV mutation status. These findings can contribute to a broader understanding of the disease.
Additional assessments may include:
The type and timing of testing can vary depending on an individual's clinical situation. Some people may undergo regular monitoring after diagnosis, while additional testing may be considered when healthcare professionals need updated information about the condition. Results from laboratory tests, physical examinations, and genetic assessments are interpreted together to support an accurate and detailed understanding of chronic lymphocytic leukemia.